These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36644105)

  • 1. A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose.
    Finsterer J
    Cureus; 2022 Dec; 14(12):e32433. PubMed ID: 36644105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of clinically confirmed long post-COVID vaccination syndrome.
    Finterer J; Scorza FA
    J Clin Transl Res; 2022 Dec; 8(6):506-508. PubMed ID: 36452006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small fiber neuropathy as a complication of SARS-CoV-2 vaccinations.
    Finsterer J
    J Family Med Prim Care; 2022 Jul; 11(7):4071-4073. PubMed ID: 36387712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.
    Serrano L; Algarate S; Herrero-Cortina B; Bueno J; González-Barriga MT; Ducons M; Montero-Marco J; Acha B; Taboada A; Sanz-Burillo P; Yuste C; Benito R;
    J Appl Microbiol; 2022 Sep; 133(3):1969-1974. PubMed ID: 35801660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
    Kong J; Cuevas-Castillo F; Nassar M; Lei CM; Idrees Z; Fix WC; Halverstam C; Mir A; Elbendary A; Mathew A
    J Infect Public Health; 2021 Oct; 14(10):1392-1394. PubMed ID: 34294590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
    Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
    Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuro-Ophthalmologic Symptoms Associated With the Moderna mRNA COVID-19 Vaccine: A Case Report.
    Raxwal T; Akel Z; Naidu J; Sundaresh K
    Cureus; 2022 Aug; 14(8):e28523. PubMed ID: 36185877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
    Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
    Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions.
    Macy E; Pandya S; Sheikh J; Burnette A; Shi JM; Chung J; Gin N; Crawford W; Zhang J
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):827-836. PubMed ID: 34971845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Dreyer N; Reynolds MW; Albert L; Brinkley E; Kwon T; Mack C; Toovey S
    Vaccine; 2022 Mar; 40(12):1904-1912. PubMed ID: 35177299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Multiple Sclerosis Uncovered Following Moderna SARS-CoV-2 Vaccination.
    Ahoussougbemey Mele A; Ogbuagu H; Parag S; Pierce B
    Cureus; 2022 Dec; 14(12):e32799. PubMed ID: 36694492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: a case report.
    Nanatsue K; Takahashi M; Itaya S; Abe K; Inaba A
    BMC Neurol; 2022 Aug; 22(1):309. PubMed ID: 35996074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report.
    Osmanodja B; Schreiber A; Schrezenmeier E; Seelow E
    BMC Nephrol; 2021 Dec; 22(1):411. PubMed ID: 34895163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Extensive Deep Vein Thrombosis After Heterogeneous Administration of Moderna mRNA Booster Vaccine: A Case Report.
    Alarmanazi F; Bangash BA; Lahoti L; Farabi B
    Cureus; 2022 Jun; 14(6):e25779. PubMed ID: 35812633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.